Natixis Advisors LLC Buys 3,909 Shares of argenx SE (NASDAQ:ARGX)

Natixis Advisors LLC grew its stake in shares of argenx SE (NASDAQ:ARGX) by 32.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 15,923 shares of the company’s stock after acquiring an additional 3,909 shares during the quarter. Natixis Advisors LLC’s holdings in argenx were worth $9,793,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ARGX. Whipplewood Advisors LLC purchased a new stake in shares of argenx during the fourth quarter valued at $37,000. Global Retirement Partners LLC boosted its position in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock valued at $38,000 after buying an additional 48 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of argenx by 1,016.7% during the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock valued at $41,000 after buying an additional 61 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of argenx by 38.2% during the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after buying an additional 21 shares during the last quarter. Finally, Venturi Wealth Management LLC purchased a new stake in shares of argenx during the fourth quarter valued at $66,000. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ARGX has been the topic of several research reports. HC Wainwright raised their target price on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. Evercore ISI raised their target price on argenx from $675.00 to $706.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. William Blair reissued an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Finally, Citigroup reissued an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $687.00.

argenx Trading Down 1.1 %

Shares of ARGX opened at $613.04 on Friday. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The business’s 50 day moving average is $635.52 and its 200 day moving average is $598.47. The company has a market capitalization of $37.25 billion, a PE ratio of -696.64 and a beta of 0.59.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. Equities research analysts predict that argenx SE will post 3.13 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.